Jasper Therapeutics, Inc.
JSPRHealthcare|Biotechnology|US
$16.86
+2.78 (+19.78%)
DCF Value
$34.77
Tangible Book / Share
$1.48
Cash / Share
$7.65
Financials
Financial Snapshot
Market Cap
$18.7M
Enterprise Value
$11.7M
Revenue (TTM)
$0.00
Net Income (TTM)
-$31.8M
Cash & Investments
$7.3M
Net Cash
$7.0M
Free Cash Flow (TTM)
-$60.3M
Operating CF (TTM)
-$60.3M
Debt/Equity
0.19
Cash Runway & Burn Rate
Cash on Hand
$7.3M
Quarterly Burn
$15.1M
Monthly Burn
$5.0M
Est. Runway
~0.5 quarters
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $27.2M | $19.8M | $84.7M | $38.3M | $86.9M | $71.6M | $28.7M | $7.3M | |
| Operating Cash Flow | -$2.0M | -$18.3M | -$33.7M | -$45.9M | -$52.1M | -$62.6M | -$77.2M | -$60.3M | |
| Free Cash Flow | -$2.0M | -$18.3M | -$36.1M | -$46.4M | -$52.3M | -$63.2M | -$77.2M | -$60.3M | |
| Capital Expenditure | $0.00 | $0.00 | -$2.4M | -$576.0K | -$267.0K | -$552.0K | -$7.0K | $0.00 | |
| Financing Cash Flow | $29.1M | $11.3M | $101.0M | $55.0K | $101.0M | $47.9M | $34.2M | $28.1M |
R&D Spending
R&D (TTM)
$36.7M
R&D Intensity
—
R&D Growth vs Prior
-39.4%
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $3.6M | $15.9M | $25.4M | $34.6M | $51.8M | $55.8M | $60.5M | $36.7M | |
| SG&A | $1.1M | $4.8M | $11.4M | $16.6M | $17.1M | $20.4M | $18.9M | $18.4M |
Income Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.1M | $21.0K | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$1.1M | -$21.0K | |
| R&D | $3.6M | $15.9M | $25.4M | $34.6M | $51.8M | $55.8M | $60.5M | $36.7M | |
| SG&A | $1.1M | $4.8M | $11.4M | $16.6M | $17.1M | $20.4M | $18.9M | $18.4M | |
| Operating Income | -$4.7M | -$20.7M | -$36.8M | -$51.2M | -$68.9M | -$76.2M | -$80.5M | -$55.2M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$5.0M | -$31.7M | -$30.6M | -$37.7M | -$64.5M | -$71.3M | -$75.8M | -$31.8M | |
| Net Income | -$5.0M | -$31.7M | -$30.6M | -$37.7M | -$64.5M | -$71.3M | -$75.8M | -$31.8M | |
| EPS (Diluted) | 0.00 | -5492.40 | -806.70 | -309.90 | -185.40 | -146.70 | -118.50 | -47.70 | |
| EBITDA | $0.00 | -$20.7M | -$30.3M | -$36.7M | -$63.4M | -$69.9M | -$74.7M | -$31.2M | |
| Shares Out. (M) | 0.01 | 0.01 | 0.04 | 0.12 | 0.35 | 0.49 | 0.64 | 0.96 |
Balance Sheet
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $27.2M | $19.8M | $84.7M | $38.3M | $86.9M | $71.6M | $28.7M | $7.3M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $27.2M | $20.7M | $87.8M | $41.7M | $88.9M | $75.8M | $34.6M | $11.6M | |
| Total Assets | $27.2M | $23.4M | $93.7M | $48.4M | $94.9M | $79.9M | $35.8M | $11.8M | |
| Total Current Liabilities | $2.0M | $4.0M | $8.0M | $7.1M | $12.4M | $15.2M | $13.2M | $7.8M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $6.1M | $58.5M | $24.1M | $12.4M | $16.5M | $18.2M | $31.6M | $10.4M | |
| Stockholders' Equity | $21.1M | -$35.1M | $69.5M | $36.0M | $78.4M | $61.7M | $4.2M | $1.4M | |
| Retained Earnings | -$5.1M | -$36.8M | -$67.5M | -$105.1M | -$169.6M | -$240.9M | -$316.7M | -$320.6M |
Cash Flow Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.0M | -$18.3M | -$33.7M | -$45.9M | -$52.1M | -$62.6M | -$77.2M | -$60.3M | |
| Capital Expenditure | $0.00 | $0.00 | -$2.4M | -$576.0K | -$267.0K | -$552.0K | -$7.0K | $0.00 | |
| Free Cash Flow | -$2.0M | -$18.3M | -$36.1M | -$46.4M | -$52.3M | -$63.2M | -$77.2M | -$60.3M | |
| Investing Cash Flow | $0.00 | $0.00 | -$2.4M | -$576.0K | -$267.0K | -$532.0K | $5.0K | $80.0K | |
| Financing Cash Flow | $29.1M | $11.3M | $101.0M | $55.0K | $101.0M | $47.9M | $34.2M | $28.1M | |
| Issuance of Stock | $0.00 | $0.00 | $236.0K | $55.0K | $101.5M | $47.2M | $34.2M | $183.0K | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $1.5M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $6.0K | $1.2M | $1.0M | $0.00 | $5.2M | $6.6M | $6.7M | $3.8M | |
| Net Change in Cash | $27.2M | -$7.0M | $64.9M | -$46.5M | $48.6M | -$15.3M | -$42.9M | -$32.2M |
Dilution Tracker
Shares outstanding grew 10981.1% over 5 years — significant dilution
Shares Outstanding
1M
5-Year Share Growth
+10981.1%
Stock Issuance (TTM)
$183.0K
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.01 | 0.01 | 0.04 | 0.12 | 0.35 | 0.49 | 0.64 | 0.96 | |
| Change vs Prior % | — | -1.7% | 558.7% | 220.2% | 186.1% | 39.7% | 31.4% | 49.7% | |
| Stock Issuance | $0.00 | $0.00 | $236.0K | $55.0K | $101.5M | $47.2M | $34.2M | $183.0K | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $6.0K | $1.2M | $1.0M | $0.00 | $5.2M | $6.6M | $6.7M | $3.8M |
Margins & Profitability
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| ROE % | -23.6% | 90.1% | -44.1% | -104.7% | -82.2% | -115.6% | -1826.1% | -618.9% | |
| ROA % | -18.3% | -135.6% | -32.7% | -77.9% | -67.9% | -89.2% | -211.9% | -269.2% | |
| ROIC % | -18.7% | -106.9% | -42.8% | -121.4% | -82.5% | -116.0% | -338.1% | -1305.0% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -339.1% | -78.1% | -39.0% | -34.5% | -10.7% | -5.6% | |
| Net Income | 0.0% | -535.0% | 3.3% | -23.0% | -71.1% | -10.6% | -6.4% | |
| EPS (Diluted) | 0.0% | 0.0% | 85.3% | 61.6% | 40.2% | 20.9% | 19.2% | |
| Operating Cash Flow | 0.0% | -827.7% | -84.4% | -36.2% | -13.5% | -20.2% | -23.3% | |
| Free Cash Flow | 0.0% | -827.7% | -97.7% | -28.6% | -12.7% | -20.7% | -22.2% | |
| R&D Expense | 0.0% | 339.0% | 60.1% | 36.2% | 49.6% | 7.8% | 8.4% | |
| SG&A Expense | 0.0% | 339.6% | 137.8% | 45.2% | 3.1% | 19.6% | -7.2% | |
| Total Assets | 0.0% | -14.2% | 301.0% | -48.4% | 96.2% | -15.8% | -55.2% | |
| Book Value / Share | 0.0% | -270.4% | 129.9% | -83.8% | -23.8% | -43.7% | -94.9% | |
| Debt | 0.0% | 0.0% | 77.6% | 26.6% | -23.7% | -34.9% | -31.9% | |
| Diluted Shares | 0.0% | -1.7% | 558.7% | 220.2% | 186.1% | 39.7% | 31.4% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B11.41
10Y Low / Med / High0.49 / 1.29 / 8.45
EV/EBITDAAt Loss
10Y Low / Med / High0.03 / 0.05 / 0.46
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$34.77
Tangible Book / Share
$1.48
Net Current Assets / Share
$1.07
Cash / Share
$7.65
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -3.47 | -0.55 | -2.92 | -0.47 | -1.28 | -4.37 | -0.46 | -0.35 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 0.82 | -0.49 | 1.29 | 0.49 | 1.05 | 5.06 | 8.45 | 11.41 | |
| EV/EBITDA | 0.00 | 0.05 | -0.25 | 0.46 | 0.03 | -3.46 | -0.10 | -0.37 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-45.46
Distress
Piotroski F-Score
0
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $6.0M | $173.8K | $67.3M |
| Net Income | -$310.0K | -$450.3K | -$347.2K |
| EPS | $-0.46 | $-0.52 | $-0.54 |
| # Analysts (EPS) | 2 | 2 | 1 |